A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 6000
- Population
- ALL · 18 Years
- Duration
- 2022-11-21 to 2027-11-30
- Intervention
- Faricimab; Port Delivery System with Ranibizumab
- Comparator
- Not reported
- Outcomes measured
- Change in Visual Acuity from Baseline at 1 Year, per Approved Retinal Indication and Product — Baseline and 1 year; Change in Visual Acuity from Baseline Over Time, per Approved Retinal Indication and Product — Baseline, 3, 6, and 12 m…; Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time, per Approved Ret…; Number of Treatments Over Time, per Approved Retinal Indication and Product — At 3, 6, and 12 months, and annually ther…; Cumulative Time Spent on Each Treatment per Eye, Overall and per Treatment Regimen (Fixed, Treat-and-Extend, As Needed,…; Percentage of Eyes with Treatment Switch by Reason for Switch Over Time, per Approved Retinal Indication and Product —…; Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Ov…; Total Number of Visits per Year, per Approved Retinal Indication and Product — Annually (up to 5 years); Number of Visits With or Without Treatment per Year, per Approved Retinal Indication and Product — Annually (up to 5 ye…; Time Interval Between Treatments per Year, per Approved Retinal Indication and Product — Annually (up to 5 years); Number of Eyes Treated with Ocular Concomitant and Subsequent Medications by Type and Frequency During the Study, per A…; Change in Visual Acuity from Baseline Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or…; Change in Visual Acuity from Baseline Over Time, According to Number of Treatments, per Approved Retinal Indication and…; Change in Visual Acuity from Baseline Over Time, According to Total Number of Visits, per Approved Retinal Indication a…; Change in Visual Acuity from Baseline Over Time, According to Treatment Schedule, per Approved Retinal Indication and P…; Change in Central Subfield Thickness (CST) from Baseline Over Time, per Approved Retinal Indication and Product — Basel…; Number of Participants with at Least One Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indica…; Number of Participants with at Least One Non-Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal In…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.